Denali Therapeutics Inc.

Denali Therapeutics, a South San Francisco biopharma, develops first‑in‑class therapeutics for neurodegenerative and lysosomal storage diseases. Its portfolio spans LRRK2, RIPK1 and OTV enzyme‑delivery platforms, with collaborations from Takeda, Genentech, and Sanofi.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical and Diagnostic Laboratories

Employees: 517
HQ: South San Francisco

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
DNLI	Denali Therapeutics Inc. Cap: 2.7B	EQUITY	NMS	USD	US24823R1059	Active	📈